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The title compound, 1-[3,5-bis(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl]propan-1-one (2), is 
synthesized by the reaction of 4,4'-difluoro chalcone (1) and hydrazine hydrate in propionic acid. 
The synthesized compound (2) is well characterized by IR, 1H-NMR, 13C-NMR, LCMS data and 
elemental analysis. The proposed structure is further confirmed by determining its single crystal 
XRD data. The compound crystallizes in the monoclinic space group P21/c, with a = 9.9470 (1) 
Å, b = 14.7200 (2) Å, c = 12.7390 (2) Å, β = 122.0700(4)°, V = 1580.61 (4) Å3, Z = 4, S = 0.95, 
R[F2 > 2σ(F2)] = 0.085, wR(F2) = 0.247. The pyrazole ring adopts an envelope conformation 
and makes the dihedral angles of 2.8(2) and 81.9(3)°, respectively, with the two fluoro-
substituted benzene rings. The dihedral angle between the two fluoro-substituted benzene rings is 
79.6(3)°. The crystal packing is stabilized by C—H...O hydrogen bonds, forming zigzag C(7) 
chains along [001]. 
 






Pyrazolines are well-known nitrogen-containing five-membered heterocyclic compounds having 
various pharmaceutical applications. In particular, they are used as antitumor, antibacterial, 
antifungal, antiviral, antiparasitic, anti-tubercular and insecticidal agents [1-3]. Some of these 
compounds have also anti-inflammatory, anti-diabetic, anaesthetic and analgesic properties [4-6]. 
In addition, pyrazolines have played a crucial part in the development of theory in heterocyclic 
chemistry and also used extensively in organic synthesis [7]. In view of the importance of 
pyrazoline derivatives and in continuation of our work on synthesis of various derivatives of 4,4'-




diflouro chalcone [8-16], the title compound (2) is synthesized and its crystal structure is 
reported here.  
 
MATERIALS AND METHODS 
 
Melting point was taken in open capillary tube and was uncorrected. The purity of the compound 
was confirmed by thin layer chromatography using Merck silica gel 60 F254 coated aluminium 
plates. IR spectrum was recorded on Shimadzu-FTIR Infrared spectrometer in KBr (mmax in 
cm−1). 1H (400 MHz) NMR spectrum was recorded on a Bruker AMX 400 spectrometer, with 5 
mm PABBO BB -1H TUBES and 13C (100 MHz) NMR spectrum was recorded for 
approximately 0.03 M solutions in DMSO-d6 at 100 MHz with TMS as internal standard. LCMS 
was obtained using Agilent 1200 series LC and Micromass zQ spectrometer. Elemental analysis 
was carried out by using VARIO EL-III (Elementar Analysensysteme GmBH). 
 
Synthesis of 1-[3,5-Bis(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl]propan-1-one 
A mixture of 4,4'-difluoro chalcone 1 (2.44 g, 0.01 mol) and hydrazine hydrate (0.5 ml, 0.01 
mol) in 25 ml propionic acid was refluxed for 8 h. The reaction mixture was cooled and poured 
into 50 ml ice-cold water. The precipitate was collected by filtration and purified by 
recrystallization from ethanol. The pale-yellow block-like crystals were grown from DMF by 
slow evaporation method and yield of the compound was 83%.  
Melting point: 104–106 °C.  
 
IR (KBr): νmax (cm−1), 3078 (Ar-H), 2960, 2937, 2873 (C-H aliphatic), 1658 (C=O), 1602, 1512 
(C=C aromatic), 1222 (C-F).  
 
1H NMR (400 MHz, DMSO-d6): δ/ppm, 1.02 (t, 3H, CH3), 2.67-2.74(q, 2H, COCH2), 3.10-3.16 
(dd, 1H, CH2-HA, JAB =18.13 Hz, JAX = 4.37 Hz),  3.79-3.86 (dd, 1H, CH2-HB, JBA =18.13 Hz, JBX 
= 11.97 Hz), 5.52-5.56 (dd, 1H, pyrazoline 5C-H, JXB = 11.79, JXA = 4.38 Hz), 7.11-7.84(m, 8H, 
Ar-H).  
 
13C NMR (100 MHz, DMSO-d6): δ/ppm, 8.94 (CH3), 26.91 (C-4 of pyrazole), 41.88 (C-5 of 
pyrazole), 59.02 (CH2), 115.25 (d), 115.72 (d), 127.53 (q), 128.93 (d), 138.61 (d), 153.15, 
160.08, 162.02 (d), 164.94, 170.85 (C=O). 
 
 LCMS: m/z = 314.9 (M+).  
 
Elemental analysis: Calculated for C18H16 F2N2O, C, 68.78%, H, 5.13%, N, 8.91%; Found: C, 
68.76%, H, 5.16%, N, 8.87%. 
 
X-ray Data Collection and Structure Refinement 
A suitable crystal was selected for structure determination by single-crystal X-ray diffraction. 
Diffraction data collection was performed on a Rigaku R-AXIS RAPID-S diffractomer equipped 
with a MoKα radiation (λ = 0.71073 Å) at 294(2) K. The data were processed using 
CrystalClear. An empirical absorption correction was applied using XABS2 [25].  
 




A summary of the experimental details for compound 2 is given in Table 1. The structure was 
solved by direct methods using SIR-97 [26]. H atoms were placed in their calculated positions 
(C—H = 0.93-0.98 Å) and refined using a riding model with Uiso(H) = 1.2 or 1.5Ueq(C). Owing 
to the poor diffraction quality of the crystal, the ratio of observed to unique reflections is low 
(33%). The structure was refined by full-matrix least-squares with SHELX-97 [27], refining on 
F2.  
 
RESULTS AND DISCUSSION 
 
One of the most convenient method for the synthesis of pyrazolines is the reaction of α,β-
unsaturated ketones with hydrazine hydrate and its derivatives. The title compound (2) is 
synthesized by the reaction of 4,4'-difluoro chalcone (1) with hydrazine hydrate in propionic acid 
under reflux condition [17].  
 
















The purity of the compound is checked by single-spot TLC, and the compound is characterized 
on the basis of spectral data (IR, NMR and LCMS) and elemental analysis. Spectral data of the 
synthesized compound 2 is in full agreement with its proposed structure. In the IR spectrum 
absorption bands at 2960, 2937, 2873 cm−1 are due to aliphatic CH groups and an absorption 
band at 1658 cm-1 is due to carbonyl group. In 1H-NMR spectrum, the signals of the respective 
protons of the title compound are verified on the basis of their chemical shifts, multiplicities, and 
coupling constants. The formation of pyrazoline ring is confirmed by the appearance of ABX 
system in 1H NMR due to geminal-vicinal coupling between protons HA and HB at C-4 and HX at 
C-5. HA which appeared as doublet of doublet at δ 3.10-3.16 ppm is the proton trans to HX and 
geminal to HB (JAB =18.13 Hz, JAX = 4.37 Hz). HB is the proton cis and vicinal to HX and 
appeared as doublet of doublet at δ 3.79-3.86 ppm (JBA =18.13 Hz, JBX = 11.97 Hz). While, HX 
appeared as doublet of doublet at δ 5.52-5.56 ppm (JXB = 11.79, JXA = 4.38 Hz) [18]. Beside 
these signals, the protons of ethyl group appeared as a triplet and quartet at δ 1.02 and 2.67 ppm 
respectively. The 13C-NMR spectrum shows peak at δ 170.85 ppm for a carbonyl carbon. Due to 
the para-fluoro substituents in two phenyl rings, six phenyl carbon signals of these two rings are 
split into doublets by 1, 2 and 3 bond coupling with 19F. The mass spectrum shows the presence 
of a peak at m/z 314.9 (M+) in accordance with the molecular formula. Elemental analysis also 
gives satisfactory results for the title compound.  
 
Crystal Structure Determination 
In the title molecule 2, (Fig. 1), all the bond lengths and angles are consistent with those of our 
similar compounds previously reported [12, 19, 20]. Selected bond lengths and bond angles of 2 
are listed in Table 2. The pyrazole ring (N(1)/N(2)/C(7)–C(9)) has an envelope conformation 




[puckering parameters [21]: q2 = 0.118(6) Å and φ = 259(3) °] with the C(9) atom bonded to the 
fluorophenyl group at the flap.  
 
The pyrazole ring makes the dihedral angles of 2.8(2) and 81.9(3)°, respectively, with the two 
fluoro-substituted benzene rings (C(1)–C(6) and C(10)–C(15)) which they form dihedral angles 
of 5.6 (2) and 75.7 (3)°, respectively, with the plane [r.m.s. deviation = 0.006 Å] defined by the 
O(1), N(1), N(2), C(9) and C(16)–C(18) atoms.  
 
Figure 1. The title molecule (2) showing the atom labeling scheme. Displacement ellipsoids for non-H  atoms 
are drawn at the 30% probability level. 
 



























Empirical formula C18H16F2N2O  
Formula weight 314.33 
Crystal size (mm3) 0.20 × 0.20 × 0.20 
Crystal system Monoclinic 
Space group P21/c  
a (A) 9.9470 (1)  
b (A) 14.7200 (2) 
c (A) 12.7390 (2) 
β (°) 122.0700(4) 
V (A3) 1580.61 (4)  
Z 4 
Dc (g·cm-3) 1.321 
µ (mm-1) 0.10 
F(000) 656 
θ range for data collection (°) 2.3, 26.4 
independent reflections 3214 
Observed reflections (I > 2 σ(I)) 1055 
Parameters 210 
R/wR (I > 2 σ(I)) 0.085/0.247 
S on F2 0.95 
(∆/σ)max <0.0001 
∆ρmax (e Å-1) 0.17 
∆ρmin (e Å-1) -0.19 




In the crystal structure, molecules are linked via C(11)—H(11)...O(1)i [symmetry code: (i) x, 
1/2-y, -1/2+z; H...A = 2.42 Å, D...A = 3.190 (7) Å, D—H...A = 141°] hydrogen bonds, forming 
zigzag C(7) chains [22, 23] along [001], (see Fig. 2 drawn by using PLATON [24]). 
 
Table 2.   Selected Bond Lengths (Å) and Bond Angles (°) for observed unit cell Molecule 2  (Standard 
deviations in parentheses) 
 
Designation Parameter 
F(1)—C(3) 1.368 (7) 
F(2)—C(13) 1.370 (7) 
O(1)—C(16) 1.221 (8) 
N(1)—N(2) 1.391 (8) 
N(1)—C(7) 1.276 (10) 
N(2)—C(9) 1.484 (9) 
N(2)—C(16) 1.365 (10) 
N(2)—N(1)—C(7) 108.1 (6) 
N(1)—N(2)—C(9) 113.8 (5) 
N(1)—N(2)—C(16) 122.2 (6) 
C(9)—N(2)—C(16) 124.0 (6) 
F(1)—C(3)—C(2) 118.7 (7) 
F(1)—C(3)—C(4) 118.1 (7) 
N(1)—C(7)—C(6) 121.1 (7) 
N(1)—C(7)—C(8) 113.5 (6) 
N(2)—C(9)—C(8) 100.5 (5) 
N(2)—C(9)—C(10) 111.0 (5) 
F(2)—C(13)—C(12) 119.5 (6) 
F(2)—C(13)—C(14) 117.0 (7) 
O(1)—C(16)—N(2) 120.3 (8) 
O(1)—C(16)—C(17) 123.1 (7) 
N(2)—C(16)—C(17) 116.5 (6) 
 
Figure 2. View of the packing diagram and hydrogen bonding of 2 viewed down the b axis. H 
atoms not involved in hydrogen bonds have been omitted for clarity. 
 
 






A pyrazoline derivative, 1-[3,5-bis(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl]propan-1-one, 
was synthesized and well characterized by IR, 1H-NMR, 13C-NMR, LCMS and single crystal 
XRD data. 
 
Supplementary Materials  
CCDC 827252 contains the supplementary crystallographic data for this paper. These data can be 
obtained free of charge from the Cambridge Crystallographic Data Centre, 12 Union Road, 
Cambridge CB2 1EZ, UK; fax: (+44) 1223 336 033; or e-mail: deposit@ccdc.cam.ac.uk. 
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